Andreas Scheel
Directeur/Bestuurslid bij Pancella Therapeutics, Inc.
Actieve functies van Andreas Scheel
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Pancella Therapeutics, Inc.
Pancella Therapeutics, Inc. BiotechnologyHealth Technology Pancella Therapeutics, Inc. develops novel therapies for geno dermatoses. The company is headquartered in Toronto, Canada. | Directeur/Bestuurslid | - | - |
panCELLa, Inc.
panCELLa, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine. | Directeur/Bestuurslid | - | - |
Loopbaan van Andreas Scheel
Statistieken
Internationaal
Canada | 3 |
Operationeel
Director/Board Member | 2 |
Sectoraal
Health Technology | 2 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Pancella Therapeutics, Inc.
Pancella Therapeutics, Inc. BiotechnologyHealth Technology Pancella Therapeutics, Inc. develops novel therapies for geno dermatoses. The company is headquartered in Toronto, Canada. | Health Technology |
panCELLa, Inc.
panCELLa, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Pluristyx, Inc., panCELLa, Inc. is a privately held early-stage biotechnology firm based in Toronto, CA. panCELLa was acquired by Pluristyx, Inc. on October 06, 2022. panCELLa has secured partnerships with several biotechnology partners to enhance its patent position and provide expanded access to its exclusive failsafe™ and cloaked cells™/iact cells. The Canadian company continues its internal R & D efforts to develop additional novel uses of its platform technologies in areas such as bio-production, cancer vaccination, and tolerization. The company was founded in 2015 by Armand Keating and Andras Nagy, and has created platforms that allow for the development of safe, universal, cost-effective, “ off-the-shelf ” therapeutic cell products for medicine. | Commercial Services |
- Beurs
- Insiders
- Andreas Scheel
- Ervaring